Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC

Liver Cancer Clinical Trial

Official title:

Investigation of Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04926376
• Other study ID #: ABK-QA-PROT-37
• Status: Completed
• Phase: N/A
• Start date: November 2, 2021
• Est. completion date: November 13, 2023

Study information

• Verified date: November 2023
• Source: ABK Biomedical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of treatment with Eye90 microspheres in patients with unresectable Hepatocellular Carcinoma (HCC) and metastatic Colorectal Cancer (mCRC). Both cause tumors, known as malignant hyper-vascular hepatic neoplasia, that have an abnormally large number of blood vessels attached to them. Eye90 is internal radiation brachytherapy for treatment of malignant hyper-vascular hepatic neoplasia that uses microspheres, tiny glass beads smaller in diameter than a human hair, to provide radiation. The microspheres contain Yttrium-90 (Y90) as the radiation source, which are used to to kill cancer cells and shrink tumors. The microspheres are also radiopaque, which means that they can be seen during imaging procedures. The visibility of the microspheres allows the study doctor to confirm the microspheres have been delivered in the tumor; this may help to improve the outcome of treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: November 13, 2023
• Est. primary completion date: November 13, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Measurable disease defined as at least one unidimensional measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI).
• Must have at least one lesion > 2 cm within the target perfused volume.
• At least one lesion must meet the definition of target lesion as defined by RECIST 1.1 or mRECIST.
• Total linear length of all lesions must be = 9 cm.
• Must have preservation of >700cc of normal liver parenchyma outside of treated volume.
• Hypervascular lesions on CT scan with 99mTC MAA SPECT/CT T:N ratio 3:1 or higher and Hypervascular on CBCT.
• No prior locoregional therapies in the liver other than previous Drug Eluting Bead TACE and/or local HCC recurrence after thermal ablation. Last TACE and/or ablation treatment must be at least 3 months prior to informed consent. Prior Lumi or Lipiodol TACE is not allowed.
• Life expectancy of = 6 months.
• = 18 years old.

Exclusion Criteria:

• Hemoglobin = 85 mg/L.
• Platelet count < 50,000/microliter or prothrombin (PT) activity > 50% normal
• INR > 1.4 (if anticoagulated, reversal must be achieved prior to any angiographic procedures).
• ALT > 2.5x upper limit
• AST > 2.5x upper limit
• For HCC subjects, Bilirubin = 2 mg/dL.
• For mCRC subjects, Bilirubin = 1.2 mg/dL.
• eGFR = 60 mL/min/1.73 m2.
• Portal vein thrombosis (PVT).
• Incompetent biliary duct system, prior biliary intervention, or a compromised Ampulla of Vater
• Estimated lung dose > 30 Gy as calculated using the lung shunt % and partition model.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Colorectal Neoplasms
• Hepatocellular Carcinoma Non-resectable
• Liver Cancer
• Metastatic Colorectal Cancer

Intervention

Device:
• Eye90 Microspheres
Y90 glass microspheres

Locations

Country	Name	City	State
New Zealand	Auckland District Health Board	Grafton

Sponsors (1)

Lead Sponsor	Collaborator
ABK Biomedical

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of toxicity	Incidence of Adverse Events = Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0	6 months
Primary	Incidence of TESAEs	Incidence of Related Treatment Emergent Serious Adverse Events (TESAEs) according to Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0	6 months
Primary	Overall Response Rate (ORR) by RECIST 1.1	ORR is defined at Complete or Partial Response using local RECIST 1.1 compared to baseline	6 months
Primary	Overall Response Rate (ORR) by mRECIST	ORR is defined at Complete or Partial Response using local mRECIST compared to baseline	6 months